223 related articles for article (PubMed ID: 19261604)
1. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.
Zhou X; Agazie YM
J Biol Chem; 2009 May; 284(18):12226-34. PubMed ID: 19261604
[TBL] [Abstract][Full Text] [Related]
2. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).
Hartman Z; Geldenhuys WJ; Agazie YM
J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells.
Zhou XD; Agazie YM
Cell Death Differ; 2008 Jun; 15(6):988-96. PubMed ID: 18421299
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M
Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088
[TBL] [Abstract][Full Text] [Related]
5. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3.
Agazie YM; Movilla N; Ischenko I; Hayman MJ
Oncogene; 2003 Oct; 22(44):6909-18. PubMed ID: 14534538
[TBL] [Abstract][Full Text] [Related]
6. A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation.
Montagner A; Yart A; Dance M; Perret B; Salles JP; Raynal P
J Biol Chem; 2005 Feb; 280(7):5350-60. PubMed ID: 15574420
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling.
Agazie YM; Hayman MJ
Mol Cell Biol; 2003 Nov; 23(21):7875-86. PubMed ID: 14560030
[TBL] [Abstract][Full Text] [Related]
8. Src homology phosphotyrosyl phosphatase 2 mediates cisplatin-related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.
Tang C; Luo H; Luo D; Yang H; Zhou X
Oncol Rep; 2018 Feb; 39(2):611-618. PubMed ID: 29207183
[TBL] [Abstract][Full Text] [Related]
9. Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.
Fan YX; Wong L; Marino MP; Ou W; Shen Y; Wu WJ; Wong KK; Reiser J; Johnson GR
J Biol Chem; 2013 Jun; 288(23):16895-16904. PubMed ID: 23612964
[TBL] [Abstract][Full Text] [Related]
10. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis.
Zhou X; Coad J; Ducatman B; Agazie YM
Histopathology; 2008 Oct; 53(4):389-402. PubMed ID: 18643929
[TBL] [Abstract][Full Text] [Related]
11. Altered glucose homeostasis in mice with liver-specific deletion of Src homology phosphatase 2.
Matsuo K; Delibegovic M; Matsuo I; Nagata N; Liu S; Bettaieb A; Xi Y; Araki K; Yang W; Kahn BB; Neel BG; Haj FG
J Biol Chem; 2010 Dec; 285(51):39750-8. PubMed ID: 20841350
[TBL] [Abstract][Full Text] [Related]
12. Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis.
Zhao H; Martin E; Matalkah F; Shah N; Ivanov A; Ruppert JM; Lockman PR; Agazie YM
Oncogene; 2019 Mar; 38(13):2275-2290. PubMed ID: 30467378
[TBL] [Abstract][Full Text] [Related]
13. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling.
Hartman Z; Zhao H; Agazie YM
Oncogene; 2013 Aug; 32(35):4169-80. PubMed ID: 23027125
[TBL] [Abstract][Full Text] [Related]
14. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth.
Patel Y; Shah N; Lee JS; Markoutsa E; Jie C; Liu S; Botbyl R; Reisman D; Xu P; Chen H
Oncotarget; 2016 Apr; 7(14):18295-308. PubMed ID: 26918448
[TBL] [Abstract][Full Text] [Related]
15. Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2.
Zhang SQ; Tsiaras WG; Araki T; Wen G; Minichiello L; Klein R; Neel BG
Mol Cell Biol; 2002 Jun; 22(12):4062-72. PubMed ID: 12024020
[TBL] [Abstract][Full Text] [Related]
16. Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice.
Lan L; Holland JD; Qi J; Grosskopf S; Rademann J; Vogel R; Györffy B; Wulf-Goldenberg A; Birchmeier W
EMBO J; 2015 Jun; 34(11):1493-508. PubMed ID: 25736378
[TBL] [Abstract][Full Text] [Related]
17. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
18. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
19. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.
Liu JJ; Li Y; Chen WS; Liang Y; Wang G; Zong M; Kaneko K; Xu R; Karin M; Feng GS
J Hepatol; 2018 Jul; 69(1):79-88. PubMed ID: 29505847
[TBL] [Abstract][Full Text] [Related]
20. Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3.
Burks J; Agazie YM
Oncogene; 2006 Nov; 25(54):7166-79. PubMed ID: 16767162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
